June 7, 2021 10:05 AM EDTUpdated June 10, 02:50 AM

Novo Nordisk scores a win for semaglutide in obesity, potentially setting up a next-gen battle with Eli Lilly

Nicole DeFeudis

Editor

Novo Nordisk pulled a highly anticipated win for its GLP-1 therapy semaglutide in obesity on Friday, becoming the first company to get a chronic weight …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk scores a win for semaglutide in obesity, potentially setting up a next-gen battle with Eli Lilly

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

No­vo Nordisk scores a win for semaglu­tide in obe­si­ty, po­ten­tial­ly set­ting up a next-gen bat­tle with Eli Lil­ly

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novo Nordisk scores a win for semaglutide in obesity, potentially setting up a next-gen battle with Eli Lilly